Massimo Gion

10.5k total citations · 4 hit papers
139 papers, 8.1k citations indexed

About

Massimo Gion is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Massimo Gion has authored 139 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 46 papers in Molecular Biology and 36 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Massimo Gion's work include HER2/EGFR in Cancer Research (23 papers), Monoclonal and Polyclonal Antibodies Research (23 papers) and Pancreatic and Hepatic Oncology Research (16 papers). Massimo Gion is often cited by papers focused on HER2/EGFR in Cancer Research (23 papers), Monoclonal and Polyclonal Antibodies Research (23 papers) and Pancreatic and Hepatic Oncology Research (16 papers). Massimo Gion collaborates with scholars based in Italy, United Kingdom and United States. Massimo Gion's co-authors include Willi Sauerbrei, Lisa M. McShane, Sheila E. Taube, Douglas G. Altman, Gary M. Clark, Ruggero Dittadi, Aline S.C. Fabricio, Giampietro Gasparini, Gary M. Clark and Carlo Gatti and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Massimo Gion

136 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

2005 1.7k citations Massimo Gion et al. profile →
REporting recommendations for tumour MARKer prognostic studies (REMARK)

2005 1.0k citations Massimo Gion et al. profile →
REporting recommendations for tumor MARKer prognostic studies (REMARK)

2006 660 citations Massimo Gion et al. profile →
Reporting Recommendations for Tumor Marker Prognostic Studies

2005 613 citations Massimo Gion et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Massimo Gion Italy	30	3.8k	3.2k	2.6k	1.5k	835	139	8.1k
Sheila E. Taube United States	21	4.5k 1.2×	3.2k 1.0×	3.5k 1.3×	1.8k 1.2×	1.0k 1.2×	38	9.0k
Giampietro Gasparini Italy	43	4.1k 1.1×	5.0k 1.6×	3.4k 1.3×	1.5k 1.0×	790 0.9×	170	9.8k
Vesa Kataja Finland	49	4.0k 1.0×	2.5k 0.8×	2.3k 0.9×	2.1k 1.4×	938 1.1×	176	9.1k
Fabio Puglisi Italy	43	4.8k 1.2×	2.3k 0.7×	2.5k 0.9×	2.4k 1.6×	861 1.0×	359	8.3k
George Somlo United States	51	6.1k 1.6×	4.7k 1.5×	3.8k 1.4×	1.8k 1.2×	1.1k 1.3×	279	12.2k
Nuhad K. Ibrahim United States	42	6.3k 1.6×	2.8k 0.9×	3.9k 1.5×	1.8k 1.2×	1.0k 1.2×	145	10.0k
Siqing Fu United States	51	4.1k 1.1×	3.8k 1.2×	2.4k 0.9×	2.4k 1.6×	1.2k 1.5×	412	9.6k
Herbert A. Fritsche United States	48	5.8k 1.5×	3.4k 1.1×	3.9k 1.5×	2.8k 1.9×	916 1.1×	163	11.2k
Dick J. Richel Netherlands	43	4.5k 1.2×	3.5k 1.1×	2.2k 0.8×	1.7k 1.1×	795 1.0×	107	9.6k
J. Torhorst Switzerland	36	3.7k 0.9×	4.1k 1.3×	2.2k 0.8×	1.7k 1.1×	1.3k 1.6×	119	8.9k

Countries citing papers authored by Massimo Gion

Since Specialization

Citations

This map shows the geographic impact of Massimo Gion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Gion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Gion more than expected).

Fields of papers citing papers by Massimo Gion

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Massimo Gion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Gion. The network helps show where Massimo Gion may publish in the future.

Co-authorship network of co-authors of Massimo Gion

This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Gion. A scholar is included among the top collaborators of Massimo Gion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Gion. Massimo Gion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravaggi, Antonella, Cássia T. Bergamaschi, Laura Zanotti, et al.. (2024). Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis. Biomedicines. 12(10). 2393–2393. 4 indexed citations

Trevisiol, Chiara, Massimo Gion, Alberto Vaona, et al.. (2021). The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. Oral Oncology. 114. 105128–105128. 17 indexed citations

Canova, Cristina, Giulia Barbieri, Maryam Zare Jeddi, et al.. (2020). Associations between perfluoroalkyl substances and lipid profile in a highly exposed young adult population in the Veneto Region. Environment International. 145. 106117–106117. 80 indexed citations

Fabricio, Aline S.C., et al.. (2019). Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels. Scandinavian Journal of Clinical and Laboratory Investigation. 79(4). 260–267. 4 indexed citations

Trevisiol, Chiara, Michela Cinquini, Aline S.C. Fabricio, Massimo Gion, & Anne WS Rutjes. (2019). Insufficient uptake of systematic search methods in oncological clinical practice guideline: a systematic review. BMC Medical Research Methodology. 19(1). 180–180. 6 indexed citations

Piovano, Elisa, Chiara Macchi, Cesare Romagnolo, et al.. (2014). The Role of HE4 in Ovarian Cancer Follow-up. International Journal of Gynecological Cancer. 24(8). 1359–1365. 35 indexed citations

Saracchini, Silvana, Luisa Foltran, S. Sulfaro, et al.. (2013). Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. The Breast. 22(6). 1101–1107. 19 indexed citations

Kulasingam, Vathany, Yingye Zheng, Antoninus Soosaipillai, et al.. (2009). Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. International Journal of Cancer. 125(1). 9–14. 52 indexed citations

Bandiera, Elisabetta, Laura Zanotti, Eliana Bignotti, et al.. (2009). Human Kallikrein 5. International Journal of Gynecological Cancer. 19(6). 1015–1021. 14 indexed citations

10.

Roveri, Antonella, Mattia Zaccarin, Pierluigi Mauri, et al.. (2008). Differential liquid phase proteomic analysis of the effect of selenium supplementation in LNCaP cells. Journal of Chromatography B. 865(1-2). 63–73. 4 indexed citations

11.

Molina, Rafael, Massimo Gion, Axel M. Gressner, et al.. (2008). Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine (CCLM). 46(5). 588–99. 9 indexed citations

12.

Stieber, P, Rafael Molina, Massimo Gion, et al.. (2008). Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® GI Monitor assay on the UniCel® DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine (CCLM). 46(5). 600–11. 16 indexed citations

13.

Gasparini, Giampietro, et al.. (2005). Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Annals of Oncology. 16(12). 1867–1873. 19 indexed citations

14.

Gion, Massimo, Patrizia Boracchi, Ruggero Dittadi, et al.. (2002). Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. European Journal of Cancer. 38(9). 1181–1188. 47 indexed citations

15.

Dittadi, Ruggero, et al.. (2001). Evaluation of HER-2/neu in Serum and Tissue of Primary and Metastatic Breast Cancer Patients using an Automated Enzyme Immunoassay. The International Journal of Biological Markers. 16(4). 255–261. 31 indexed citations

16.

Dittadi, Ruggero, et al.. (1996). c‐erbB‐2/neu protein expression, DNA ploidy and S phase in breast cancer. Cell Proliferation. 29(7). 403–412. 3 indexed citations

17.

Boccardo, Francesco, Paolo Bruzzi, L. Cionini, et al.. (1995). Appropriateness of the use of clinical and radiologic examinations and laboratory tests in the follow-up of surgically-treated breast cancer patients. Annals of Oncology. 6. S57–S59. 4 indexed citations

18.

Gion, Massimo, R. Mione, Gianni Cappelli, et al.. (1995). Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment. Annals of Oncology. 6. S31–S35. 23 indexed citations

19.

Gion, Massimo, et al.. (1994). Tissue Polypeptide Antigen and Tissue Polypeptide Specific Antigen in Primary Breast Cancer. Evaluation in Serum and Tutmour Tissue. Clinical Chemistry and Laboratory Medicine (CCLM). 32(10). 779–87. 2 indexed citations

20.

Gion, Massimo, et al.. (1988). Tumor marker radioimmunoassays in gastric juice. Gastroenterology. 94(6). 1271–1275. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact